Predictive factors of aGVHD (grade 1-4) development
| Baseline parameters . | Hazard ratio (95% CI; modeling the risk of aGVHD) . | P . |
|---|---|---|
| Univariate analysis | ||
| iNKT/T ratio | ||
| < 10−3 | 1* | |
| ≥ 10−3 | 0.12 (0.03-0.40)* | < .001* |
| Sex | ||
| Male | 1 | |
| Female | 1.13 (0.61-2.10) | .689 |
| Age of recipient, y | ||
| < 45 | 1 | |
| ≥ 45 | 1.63 (0.84-3.152) | .145 |
| Age of donor, y | ||
| < 35 | 1 | |
| ≥ 35 and < 45 | 1.81 (0.82-3.97) | .139 |
| ≥ 45 | 1.57 (0.74-3.32) | .235 |
| Disease status at transplantation | ||
| CR | 1 | |
| PR or SD | 1.59 (0.83-3.03) | .158 |
| PD | 1.92 (0.55-6.59) | .300 |
| Conditioning regimen | ||
| MAC | 1 | |
| RIC | 0.69 (0.36-1.28) | .250 |
| Donor | ||
| Sibling | 1* | |
| Unrelated (10/10 or 9/10) | 2.66 (1.43-4.94)* | .001* |
| Donor/recipient sex matching | ||
| Female to male | 0.79 (0.36-1.71) | .553 |
| Other | 1 | |
| In vivo T depletion | ||
| No | 1 | |
| Yes | 0.72 (0.38-1.35) | .307 |
| Risk of CMV | ||
| Low | 1 | |
| Intermediate | 1.00 (0.47-2.14) | .988 |
| High | 1.27 (0.57-2.84) | .554 |
| Type of graft | ||
| BM | 1 | |
| PBMC | 0.61 (0.32-1.18) | .147 |
| Multivariate analysis | ||
| iNKT/T ratio | ||
| < 10−3 | 1* | |
| ≥ 10−3 | 0.13 (0.03-0.44)* | .001* |
| Donor | ||
| Sibling | 1* | |
| Unrelated (10/10 or 9/10) | 2.36 (1.27-4.39)* | .006* |
| Baseline parameters . | Hazard ratio (95% CI; modeling the risk of aGVHD) . | P . |
|---|---|---|
| Univariate analysis | ||
| iNKT/T ratio | ||
| < 10−3 | 1* | |
| ≥ 10−3 | 0.12 (0.03-0.40)* | < .001* |
| Sex | ||
| Male | 1 | |
| Female | 1.13 (0.61-2.10) | .689 |
| Age of recipient, y | ||
| < 45 | 1 | |
| ≥ 45 | 1.63 (0.84-3.152) | .145 |
| Age of donor, y | ||
| < 35 | 1 | |
| ≥ 35 and < 45 | 1.81 (0.82-3.97) | .139 |
| ≥ 45 | 1.57 (0.74-3.32) | .235 |
| Disease status at transplantation | ||
| CR | 1 | |
| PR or SD | 1.59 (0.83-3.03) | .158 |
| PD | 1.92 (0.55-6.59) | .300 |
| Conditioning regimen | ||
| MAC | 1 | |
| RIC | 0.69 (0.36-1.28) | .250 |
| Donor | ||
| Sibling | 1* | |
| Unrelated (10/10 or 9/10) | 2.66 (1.43-4.94)* | .001* |
| Donor/recipient sex matching | ||
| Female to male | 0.79 (0.36-1.71) | .553 |
| Other | 1 | |
| In vivo T depletion | ||
| No | 1 | |
| Yes | 0.72 (0.38-1.35) | .307 |
| Risk of CMV | ||
| Low | 1 | |
| Intermediate | 1.00 (0.47-2.14) | .988 |
| High | 1.27 (0.57-2.84) | .554 |
| Type of graft | ||
| BM | 1 | |
| PBMC | 0.61 (0.32-1.18) | .147 |
| Multivariate analysis | ||
| iNKT/T ratio | ||
| < 10−3 | 1* | |
| ≥ 10−3 | 0.13 (0.03-0.44)* | .001* |
| Donor | ||
| Sibling | 1* | |
| Unrelated (10/10 or 9/10) | 2.36 (1.27-4.39)* | .006* |
Univariate and multivariate Cox proportional hazard ratio models considering iNKT/T ratio (repeatedly assessed on days 15, 30, 60, and 90 after HSCT) as a time-dependent variable.
CI indicates confidence interval; HSC, hematopoietic stem cell, MAC, myeloablative conditioning; PBSC, peripheral blood stem cells; and RIC, reduced-intensity conditioning.
Statistically significant.